View Future GrowthBioSmartLtd 과거 순이익 실적과거 기준 점검 5/6BioSmartLtd은 연평균 48.3%의 비율로 수입이 증가해 온 반면, Tech 산업은 수입이 30.1% 증가했습니다. 매출은 연평균 20.7%의 비율로 증가했습니다. BioSmartLtd의 자기자본이익률은 4.8%이고 순이익률은 1.9%입니다.핵심 정보48.26%순이익 성장률46.88%주당순이익(EPS) 성장률Tech 산업 성장률-2.85%매출 성장률20.71%자기자본이익률4.79%순이익률1.87%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.분석 기사 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공지 • Mar 13BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,360, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total returns to shareholders of 20% over the past three years.분석 기사 • Feb 02What BioSmart Co.,Ltd.'s (KOSDAQ:038460) 44% Share Price Gain Is Not Telling YouBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have continued their recent momentum with a 44% gain in the last month...New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩143.6b market cap, or US$99.1m).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩5,680, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 50% over the past three years.분석 기사 • Dec 15BioSmart Co.,Ltd.'s (KOSDAQ:038460) Shares Climb 44% But Its Business Is Yet to Catch UpBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have had a really impressive month, gaining 44% after a shaky period...New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩100.3b market cap, or US$68.5m).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩3,970, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 8.2% over the past three years.New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩74.9b market cap, or US$54.0m).분석 기사 • Apr 23The Market Lifts BioSmart Co.,Ltd. (KOSDAQ:038460) Shares 33% But It Can Do MoreBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders have had their patience rewarded with a 33% share price jump in the...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.03% net profit margin). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩102.7b market cap, or US$72.2m).분석 기사 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.공지 • Mar 12BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South KoreaNew Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$52.1m).분석 기사 • Nov 13BioSmart Co.,Ltd. (KOSDAQ:038460) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has fared very poorly over the last month, falling by a substantial...분석 기사 • Oct 14Here's Why We Think BioSmartLtd (KOSDAQ:038460) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩4,205, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩3,810, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 42% over the past three years.분석 기사 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jun 15BioSmart Co.,Ltd. (KOSDAQ:038460) Might Not Be As Mispriced As It Looks After Plunging 26%The BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has softened a substantial 26% over the previous 30 days, handing...Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,530, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 15x in the Tech industry in South Korea. Total loss to shareholders of 32% over the past three years.공지 • Jun 06An unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billionAn unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billion on June 4, 2024. The transaction is expected to close on June 5, 2024.Valuation Update With 7 Day Price Move • May 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩6,560, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 6.0% over the past three years.분석 기사 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,505, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 11x in the Tech industry in South Korea. Total loss to shareholders of 35% over the past three years.분석 기사 • Apr 11Further Upside For BioSmart Co.,Ltd. (KOSDAQ:038460) Shares Could Introduce Price Risks After 52% BounceThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has done very well over the last month, posting an excellent gain...New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (₩109.1b market cap, or US$79.8m).Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩4,090, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 31% over the past three years.분석 기사 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,370. The fair value is estimated to be ₩2,795, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 87%.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 65% over the past three years.New Risk • Oct 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (₩72.0b market cap, or US$53.6m).New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (₩71.8b market cap, or US$54.2m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,070, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 34% over the past three years.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩4,515, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 9.1% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩3,905, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 10x in the Tech industry in South Korea. Total loss to shareholders of 14% over the past three years.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.분석 기사 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Mar 04New 90-day low: ₩6,140The company is down 19% from its price of ₩7,600 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 20% over the same period.분석 기사 • Feb 16Returns On Capital At BioSmartLtd (KOSDAQ:038460) Paint An Interesting PictureThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...분석 기사 • Jan 29Declining Stock and Decent Financials: Is The Market Wrong About BioSmart Co.,Ltd. (KOSDAQ:038460)?It is hard to get excited after looking at BioSmartLtd's (KOSDAQ:038460) recent performance, when its stock has...Is New 90 Day High Low • Jan 29New 90-day low: ₩6,230The company is down 37% from its price of ₩9,920 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 48% over the same period.분석 기사 • Jan 11BioSmartLtd (KOSDAQ:038460) Shareholders Have Enjoyed A 51% Share Price GainBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders might be concerned after seeing the share price drop 26% in the last...Is New 90 Day High Low • Jan 08New 90-day low: ₩7,280The company is down 28% from its price of ₩10,100 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 39% over the same period.분석 기사 • Dec 23BioSmart Co.,Ltd. (KOSDAQ:038460) Looks Interesting, And It's About To Pay A DividendBioSmart Co.,Ltd. ( KOSDAQ:038460 ) is about to trade ex-dividend in the next four days. Ex-dividend means that...Upcoming Dividend • Dec 22Upcoming Dividend of ₩63.00 Per ShareWill be paid on the 7th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (1.9%).분석 기사 • Dec 17Does BioSmart Co.,Ltd. (KOSDAQ:038460) Have A Place In Your Dividend Portfolio?Dividend paying stocks like BioSmart Co.,Ltd. ( KOSDAQ:038460 ) tend to be popular with investors, and for good reason...Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩9,670, the stock is trading at a trailing P/E ratio of 58.2x, up from the previous P/E ratio of 45x. This compares to an average P/E of 24x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 110%.분석 기사 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Nov 25New 90-day low: ₩8,150The company is down 36% from its price of ₩12,800 on 27 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 22% over the same period.Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 20% share price gain to ₩11,650, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 16x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 131%.Valuation Update With 7 Day Price Move • Oct 27Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,750, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 20x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 118%.매출 및 비용 세부 내역BioSmartLtd가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A038460 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 25482,7769,00959,62669330 Sep 25475,0317,21557,64079430 Jun 25468,6061,72459,64173431 Mar 25477,902-2,20859,74976631 Dec 24484,31012759,07268030 Sep 24477,3377,12857,62195930 Jun 24472,3108,96058,92996631 Mar 24464,37719,48261,6501,12031 Dec 23456,16417,90764,1401,34130 Sep 23451,6934,46465,8881,46830 Jun 23430,6186,12165,3301,60731 Mar 23409,3442,03864,3971,32031 Dec 22391,82272162,7031,16830 Sep 22332,8562,35460,20938630 Jun 22287,7361,08458,96822531 Mar 22237,7882,90956,48532731 Dec 21189,1831,39256,41342730 Sep 21184,940-5,44058,50780430 Jun 21175,807-6,89158,0591,05131 Mar 21167,868-9,99057,8301,08831 Dec 20166,429-8,73755,5911,02930 Sep 20166,3953,24756,34593030 Jun 20167,21219,93054,69569031 Mar 20165,73220,84252,59556931 Dec 19158,96822,14749,54247730 Sep 19151,42618,04645,51741230 Jun 19143,9274,64641,38952431 Mar 19129,5296,74435,70953431 Dec 18117,7335,13531,41253430 Sep 18103,1088,64525,60456530 Jun 1892,4987,69121,07938431 Mar 1887,4895,58518,84825531 Dec 1780,4334,82616,99216830 Sep 1779,5132,59415,3759230 Jun 1774,7801,69714,2844931 Mar 1768,02749513,0937331 Dec 1662,99061911,9017930 Sep 1658,8151,61911,9769730 Jun 1655,9462,13412,12710231 Mar 1655,2041,61912,1079631 Dec 1554,1873,14811,6168830 Sep 1550,6362,17810,6917230 Jun 1546,4686509,64567양질의 수익: A038460는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A038460의 현재 순 이익률 (1.9%)은 지난해 (0.03%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A038460는 지난 5년 동안 흑자전환하며 연평균 48.3%의 수익 성장을 기록했습니다.성장 가속화: 지난 1년간 A038460 의 수익 증가율(6984.2%)은 연간 평균(48.3%)을 초과합니다.수익 대 산업: A038460의 지난 1년 수익 증가율(6984.2%)은 Tech 업계의 58%를 상회했습니다.자기자본이익률높은 ROE: A038460의 자본 수익률(4.8%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YTech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/06 12:37종가2026/05/06 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioSmart Co.,Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
공지 • Mar 13BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,360, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total returns to shareholders of 20% over the past three years.
분석 기사 • Feb 02What BioSmart Co.,Ltd.'s (KOSDAQ:038460) 44% Share Price Gain Is Not Telling YouBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have continued their recent momentum with a 44% gain in the last month...
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩143.6b market cap, or US$99.1m).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩5,680, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 50% over the past three years.
분석 기사 • Dec 15BioSmart Co.,Ltd.'s (KOSDAQ:038460) Shares Climb 44% But Its Business Is Yet to Catch UpBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have had a really impressive month, gaining 44% after a shaky period...
New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩100.3b market cap, or US$68.5m).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩3,970, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 8.2% over the past three years.
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩74.9b market cap, or US$54.0m).
분석 기사 • Apr 23The Market Lifts BioSmart Co.,Ltd. (KOSDAQ:038460) Shares 33% But It Can Do MoreBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders have had their patience rewarded with a 33% share price jump in the...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.03% net profit margin). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩102.7b market cap, or US$72.2m).
분석 기사 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
공지 • Mar 12BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South Korea
New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$52.1m).
분석 기사 • Nov 13BioSmart Co.,Ltd. (KOSDAQ:038460) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has fared very poorly over the last month, falling by a substantial...
분석 기사 • Oct 14Here's Why We Think BioSmartLtd (KOSDAQ:038460) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩4,205, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩3,810, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 42% over the past three years.
분석 기사 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jun 15BioSmart Co.,Ltd. (KOSDAQ:038460) Might Not Be As Mispriced As It Looks After Plunging 26%The BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has softened a substantial 26% over the previous 30 days, handing...
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,530, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 15x in the Tech industry in South Korea. Total loss to shareholders of 32% over the past three years.
공지 • Jun 06An unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billionAn unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billion on June 4, 2024. The transaction is expected to close on June 5, 2024.
Valuation Update With 7 Day Price Move • May 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩6,560, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 6.0% over the past three years.
분석 기사 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,505, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 11x in the Tech industry in South Korea. Total loss to shareholders of 35% over the past three years.
분석 기사 • Apr 11Further Upside For BioSmart Co.,Ltd. (KOSDAQ:038460) Shares Could Introduce Price Risks After 52% BounceThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has done very well over the last month, posting an excellent gain...
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (₩109.1b market cap, or US$79.8m).
Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩4,090, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 31% over the past three years.
분석 기사 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,370. The fair value is estimated to be ₩2,795, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 87%.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 65% over the past three years.
New Risk • Oct 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (₩72.0b market cap, or US$53.6m).
New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (₩71.8b market cap, or US$54.2m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,070, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 34% over the past three years.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩4,515, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 9.1% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩3,905, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 10x in the Tech industry in South Korea. Total loss to shareholders of 14% over the past three years.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
분석 기사 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Mar 04New 90-day low: ₩6,140The company is down 19% from its price of ₩7,600 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 20% over the same period.
분석 기사 • Feb 16Returns On Capital At BioSmartLtd (KOSDAQ:038460) Paint An Interesting PictureThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
분석 기사 • Jan 29Declining Stock and Decent Financials: Is The Market Wrong About BioSmart Co.,Ltd. (KOSDAQ:038460)?It is hard to get excited after looking at BioSmartLtd's (KOSDAQ:038460) recent performance, when its stock has...
Is New 90 Day High Low • Jan 29New 90-day low: ₩6,230The company is down 37% from its price of ₩9,920 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 48% over the same period.
분석 기사 • Jan 11BioSmartLtd (KOSDAQ:038460) Shareholders Have Enjoyed A 51% Share Price GainBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders might be concerned after seeing the share price drop 26% in the last...
Is New 90 Day High Low • Jan 08New 90-day low: ₩7,280The company is down 28% from its price of ₩10,100 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 39% over the same period.
분석 기사 • Dec 23BioSmart Co.,Ltd. (KOSDAQ:038460) Looks Interesting, And It's About To Pay A DividendBioSmart Co.,Ltd. ( KOSDAQ:038460 ) is about to trade ex-dividend in the next four days. Ex-dividend means that...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩63.00 Per ShareWill be paid on the 7th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (1.9%).
분석 기사 • Dec 17Does BioSmart Co.,Ltd. (KOSDAQ:038460) Have A Place In Your Dividend Portfolio?Dividend paying stocks like BioSmart Co.,Ltd. ( KOSDAQ:038460 ) tend to be popular with investors, and for good reason...
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩9,670, the stock is trading at a trailing P/E ratio of 58.2x, up from the previous P/E ratio of 45x. This compares to an average P/E of 24x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 110%.
분석 기사 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Nov 25New 90-day low: ₩8,150The company is down 36% from its price of ₩12,800 on 27 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 22% over the same period.
Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 20% share price gain to ₩11,650, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 16x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 131%.
Valuation Update With 7 Day Price Move • Oct 27Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,750, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 20x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 118%.